Cellumed has recruited external experts to accelerate its entry into the secondary battery new business and AI (artificial intelligence)-based surgical robot fields. Cellumed announced on the 15th through a public disclosure that it has appointed Lee Byung-gil as an inside director and Noh Doo-hyun as an outside director.
Candidate Lee, the inside director, has worked for several years as an executive at global companies in the telecommunications and electronics sectors in China, Hong Kong, and other regions. The company expects him to play an excellent role in important board decisions based on his experience as the head of the Strategic Business Division overseeing Cellumed’s secondary battery and EV business.
Cellumed is promoting a replaceable battery platform business for secondary batteries as a future strategic business. The company plans to introduce battery solutions from a leading global secondary battery company in China, mass-produce battery packs domestically, and sell them. In addition, Cellumed is preparing to produce and sell domestically electric two-wheeler models whose performance has been verified in the global market. To this end, Cellumed plans to sign a main contract with the relevant global company in China soon.
Candidate Noh Doo-hyun, an outside director, is a professor of orthopedics at Seoul National University Hospital and an outstanding talent who earned his bachelor's, master's, and doctoral degrees from Seoul National University College of Medicine. He is not only the top authority in Korea in patient-customized surgery and AI-based medical robot research and development in the field of artificial joints but also the founder of Connective, a specialized AI medical robot company that has received government support, contributing to the advancement of domestic medical technology with his unique expertise. The company explained that candidate Noh will play an important role on the board based on this professional experience.
Cellumed plans to strengthen its global competitiveness by integrating AI robot technology with its self-developed patient-customized artificial joint total replacement surgery (PSI). Amid the active adoption of AI in the medical and bio industries recently, Cellumed is promoting the advancement of PSI and software through active cooperation with AI robot companies and aims to enter the surgical robot field in the future.
A Cellumed official said, “The secondary battery and AI-based surgical robot fields not only have great growth potential but also very high entry barriers,” adding, “The two newly recruited individuals will be a great help in realizing the company’s future strategic businesses and vision based on their extensive expertise and solid networks.”
He continued, “Starting from the regular shareholders’ meeting where the two director candidates will be formally appointed, the secondary battery and EV business and AI-based medical surgical robot-related businesses will accelerate,” adding, “We will leap forward as a global company through successful business outcomes.”
Meanwhile, at the regular shareholders’ meeting, Cellumed plans to add the following business purposes related to the secondary battery replaceable battery platform: ▲manufacturing and sales of battery packs ▲manufacturing and sales of electric two-wheelers and electric vehicles ▲construction and service of replaceable battery systems ▲manufacturing and sales of replaceable battery packs for drones and ships.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
